|
Biolinerx Ltd
BLRX's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Biolinerx Ltd growth rates, revenue grew
in IV. Quarter 2023 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
deterioration of revenues by -4.85 %
Biolinerx Ltd net loss increased from $-25 millions, to $-61 millions in IV. Quarter 2023,
• More on BLRX's Growth
|
|
Biolinerx Ltd realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 39.25 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 86.56.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.33.
• More on BLRX's Valuation
|
|
|
|
|
Biolinerx Ltd realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 39.25 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 86.56.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.33.
Biolinerx Ltd Price to Book Ratio is at 31.42 lower than Industry Avg. of 81.37. and higher than S&P 500 Avg. of 0
• More on BLRX's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com